Proactive Investors - Run By Investors For Investors
Market: AIM
52-week High/Low: 240.00p / 102.06p
Sector: Pharma & Biotech
Market Cap: 201.24M
Tiziana Life Sciences

Tiziana Life Sciences

The Company acquired Tiziana Pharma Limited (“TPL”) via a reverse takeover (as defined in the AIM Rules). The acquisition completed on 24 April 2014. TPL was formed in November 2013 as a vehicle to acquire and exploit certain intellectual property in biotechnology. Its mission is to discover and develop novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers. The first of TPL’s programmes seeks to develop a drug for application in the therapeutic area of metastatic breast cancer.

Tiziana Life Sciences

Interactive graph

col 3
col 4
col 5
col 6

Tiziana Life Sciences Timeline

Columns Including TILS


Market Reports Including TILS


© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use